Thomas F. Cowhey
CIK 1735242 · View on SEC EDGAR ↗
First SEC filing: Oct. 20, 2023 · Latest: Oct. 20, 2023
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| April 1, 2025 | CVS | A | 68,621 | $67.98 | $4,664,856 | 68,621 Direct | — | Acquired | 37.7% (price as of 2026-08-21) |
| April 1, 2025 | CVS | A | 16,181 | $67.98 | $1,099,984 | 41,109 Direct | +64.91% | Acquired | 37.7% (price as of 2026-08-21) |
| April 1, 2025 | CVS | F | 3,203 | $67.98 | $217,740 | 50,188 Direct | -6.00% | Disposed | 37.7% (price as of 2026-08-21) |
| Feb. 28, 2025 | CVS | F | 5,318 | $65.72 | $349,499 | 45,256 Direct | -10.52% | Disposed | 42.4% (price as of 2026-08-21) |
| April 1, 2024 | CVS | A | 15,082 | — | — | 47,995 Direct | +45.82% | Acquired | (price as of 2026-08-21) |
| April 1, 2024 | CVS | A | 62,695 | $79.56 | $4,988,014 | 62,695 Direct | — | Acquired | 17.6% (price as of 2026-08-21) |
| April 1, 2024 | CVS | F | 1,719 | $79.56 | $136,764 | 35,642 Direct | -4.60% | Disposed | 17.6% (price as of 2026-08-21) |
| Feb. 28, 2024 | CVS | F | 5,641 | $75.19 | $424,147 | 28,631 Direct | -16.46% | Disposed | 24.5% (price as of 2026-08-21) |
| Nov. 30, 2023 | CVS | A | 7,358 | $67.95 | $499,976 | 60,938 Direct | +13.73% | Acquired | 37.7% (price as of 2026-08-21) |
| April 2, 2018 | SGRY | A | 14,749 | — | — | 14,749 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| April 1, 2025 | CVS | Stock Option [F3] | Common Stock (68,621) | $67.98 | April 2, 2035 | 68,621 | Acquired |
| April 1, 2024 | CVS | Stock Option | Common Stock (62,695) | $79.56 | April 1, 2034 | 62,695 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 4 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
CVS
CFO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $420,833 | — | — | — | $0 | $3,097 | $791,235 | $6,715,138 |
| 2024 | $998,387 | — | — | — | $436,000 | $1,713 | $208,434 | $7,644,364 |
| 2023 | $771,250 | — | $2,187,397 | $562,490 | $788,000 | $2,095 | $268,705 | $4,579,937 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.